ClinicalTrials.Veeva

Menu

Prescription Opioid Effects in Abusers Versus Non-Abusers

N

New York State Psychiatric Institute

Status and phase

Completed
Phase 2

Conditions

Opioid-Related Disorders
Substance-Related Disorders

Treatments

Drug: Placebo 0 mg
Drug: oxycodone 30 mg
Drug: oxycodone 15 mg

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT00158184
#4691
R01DA016759-01 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to examine the abuse liability of oxycodone in individuals with, and without, a history of prescription opioid abuse.

Full description

Prescription opioid abuse is becoming an increasingly widespread and serious public health concern. The 2001 National Household Survey on Drug Abuse report revealed that the number of first-time users of prescription opioid medications for non-medical reasons reached 2 million in the year 2000, a number that has quintupled since 1984. Despite this trend, little experimental research has been directed towards understanding who may be abusing these medications, and under what conditions. The study will examine the reinforcing, subjective, performance, and physiological effects of oxycodone. Because it is not clear who is abusing prescription opioids, the medication effects will be compared in drug abusers and non-drug abusers.

Enrollment

27 patients

Sex

All

Ages

21 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • In good physical health
  • Women reporting regular menstrual cycles lasting between 24 to 35 days
  • Able to perform study procedures
  • Normal body weight
  • Use of opioids for medical purposes (cough, pain, or diarrhea) or recreational purposes at least twice in lifetime with no serious adverse effects
  • Current opioid abuse, but not opioid dependence (drug abusers only)

Exclusion criteria

  • On parole or probation

  • Recently convicted of a crime of violence

  • History of significant violent behavior

  • Current Axis I psychopathology

  • Significant Axis II disorder

  • Pregnancy

  • Women who have irregular menstrual cycles, or who are dysmenorrheic, amenorrheic, or menopausal

  • Women who have been pregnant or breastfeeding within the past 6 months

  • Women who have had a miscarriage or abortion within the past 6 months

  • Women who meet DSM-IV criteria for premenstrual dysphoric disorder

  • Women who report suffering from moderate to severe premenstrual symptoms

  • Women seeking treatment for premenstrual problems

  • Taking prescription or over-the-counter psychotropic medication

  • History of chronic pain, or routinely uses over-the-counter analgesics (more than 4 days per month)

  • Blood pressure greater than 150/90 mm Hg

  • Reports of sensitivity, allergy, or contraindication to opioids

  • Non-drug abusers:

    1. Current or lifetime history of substance abuse or dependence according to DSM-IV criteria (those requiring detoxification)
    2. Consumes more than 500 mg caffeine daily
    3. Seeking treatment for substance use

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

27 participants in 2 patient groups

Rx Opioid Abusers
Active Comparator group
Description:
Recreational users of prescription opioids. Participants in this arm received the 3 interventions (0, 15, and 30 mg oxycodone) at random.
Treatment:
Drug: oxycodone 30 mg
Drug: oxycodone 15 mg
Drug: Placebo 0 mg
Rx Opioid Non-Abusers
Active Comparator group
Description:
Participants with a history of prescription opioid use, but who did not abuse them. Participants in this arm received the 3 interventions (0, 15, and 30 mg) at random.
Treatment:
Drug: oxycodone 30 mg
Drug: oxycodone 15 mg
Drug: Placebo 0 mg

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems